The delayed decision from the CHMP is another rejection for Syfovre but Apellis still hopes the regulator may be convinced in a second review later this year.

The efficacy of Moderna’s jab appears to fade faster than its rivals, while experts were surprised by an FDA panel’s recommendation to narrow the use of all three RSV vaccines.

The companies are set to present Phase III results from their rival myostatin inhibitor drugs for spinal muscular atrophy in Q4, while also fast-tracking the candidates in obesity studies.

The success in the NIAGRA bladder cancer study is welcome, but another failure in NSCLC means AstraZeneca has more riding on the AEGEAN study, with an FDA advisory board to review the lung cancer data due shortly.

A new muscle-building front is opening in the fight against obesity, with Lilly among the leaders. But it plans to remain tight-lipped on upcoming Phase II data for its myostatin inhibitor in combination with Novo’s Wegovy for fear of playing into the hands of its rival.

VX-880 is the first iteration of a cell therapy strategy which Vertex believes can bring curative treatment for Type 1 diabetes, but competition in this field is building.